Recent Press Releases

Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism

Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of...

OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial

Funding to support expanded clinical development of PVX-410 in combination with lenalidomide in patients with smoldering multiple myelomaFinancing includes equity investment from The Leukemia &...

Pfizer's Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation

August 28, 2014 08:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...

OncoMed Pharmaceuticals Announces Removal of Partial Clinical Hold by the FDA for Vantictumab

REDWOOD CITY, Calif., Aug. 28, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical...

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of...

Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA

Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA)...

Isogenica Appoints New Chief Executive Officer

Isogenica Appoints New Chief Executive Officer CAMBRIDGE, England--(BUSINESS WIRE)--Isogenica are pleased to announce the appointment of Dr. Chris Ullman as CEO with effect from September 29th 2014,...

Ebola vaccine trials fast-tracked by international consortium

28 August 2014 Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine A candidate Ebola vaccine could be given to healthy volunteers...

FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure

THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.

Early Stage Life Science Investors Converge in Fenway Park

Wednesday, September 17th, 2014 – Fenway Park, Boston, MA The Redefining Early Stage Investments (RESI) Conference is reinventing the way investors and entrepreneurs connect and share...

LIFE SCIENCES VENTURE CAPITAL INVESTMENTS SOAR IN Q2 TO HIGHEST LEVEL SINCE 2007, ACCORDING TO THE MONEYTREE REPORT

Venture Capital Dollars in Biotechnology Companies Increases Nearly 40 Percent, Strongest Second Quarter Since 1995 NEW YORK, August 25, 2014 – Venture capital (VC) funding for the Life...

Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing

Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing Investor syndicate includes leading biotech and mutual funds HOUSTON, Aug 27, 2014 (BUSINESS WIRE) -- Bellicum...

Latest ARCH Venture Partners Fund Closes Above $400 Million

Latest ARCH Venture Partners Fund Closes Above $400 Million SEATTLE, Aug. 27, 2014 /PRNewswire-USNewswire/ -- ARCH Venture Partners, one of the largest U.S. technology venture firms investing in the...

Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS

Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS WASHINGTON, Aug 27, 2014 (GLOBE NEWSWIRE...

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration Lexington, MA (August 26, 2014) -- Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today...

Civitas Therapeutics Secures $55 Million in Series C Financing

HEADLINE2Proceeds to support Phase 3 clinical trials for CVT-301 Parkinson's disease program and pipeline expansion CHELSEA, Mass., Aug 25, 2014 (BUSINESS WIRE) -- Civitas Therapeutics, Inc., a...

Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

Agreement to Combine Merck's Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer's Crizotinib (XALKORI®) in Clinical Trial Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK),...

Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roche's immunotherapy assay

Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications

PLEASA

Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI)

Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer...

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

ZUG, Switzerland, Aug 25, 2014 (PR Newswire Europe via COMTEX) -- - Clinical Candidate COVA 322 and FynomAb(R) Technology Platform Further Strengthen Immunology Portfolio and Capabilities ZUG,...